HIV AIDS

>

Latest News

Investigational Two-Drug HIV Regimen Shows Minimal Impact on Weight and Lipids in Phase 3 Trials / Image credit:  ©artegorov3@gmail/AdobeStock
Investigational Two-Drug HIV Regimen Shows Minimal Impact on Weight and Lipids in Phase 3 Trials

October 15th 2025

Merck reveals promising phase 3 results for DOR/ISL, showing minimal impact on weight and lipids in adults with suppressed HIV-1.

Phase 3 Trials Begin for Once-Monthly Oral HIV Prevention Pill
Phase 3 Trials Begin for Once-Monthly Oral HIV Prevention Pill

July 17th 2025

New Data at IAS 2025 Underscore Real-World Success of Long-Acting Injectable HIV Therapies / Image credit: ©Ezume Images/AdobeStock
New Data at IAS 2025 Underscore Real-World Success of Long-Acting Injectable HIV Therapies

July 8th 2025

 Lenacapavir Approved for Twice-Yearly Injection for HIV Prevention, a Landmark FDA Decision / image credit ©Waldenmarus/stock.adobe.com
Lenacapavir Approved for Twice-Yearly Injection for HIV Prevention, a Landmark FDA Decision

June 19th 2025

Improved HPV Vaccination Coverage May Help Prevent Noncervical Cancers in People with HIV / Image credit: ©Sherry Young/AdobeStock
Improved HPV Vaccination Coverage May Help Prevent Noncervical Cancers in People with HIV

March 19th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.